PROVETOP

Biotinylated Human ALK-7/Activin RIC Protein

Catalog No: ALK7-HB001

Species
Human
Expression System
HEK293
Tag
His, Avi
Activity
Activity verified

Product overview

Recombinant Biotinylated Human ALK-7/Activin RIC Protein is expressed in HEK293 cells with a His tag and Avi tag at the C-terminus. It contains amino acid residues Glu21-Glu113 (UniProt accession: Q8NER5-1).

Product Details

Molecular Aliases
ACTR-IC; ACVR1C; ALK7; Activin R1C;
Protein Length
Glu21-Glu113
Expression System
HEK293
Theoretical Molecular Weight
The protein has a predicted MW of 13.71 kDa. Due to glycosylation, the protein migrates to 20-40 kDa based on Bis-Tris PAGE result.
Purity
> 95% as determined by Bis-Tris PAGE > 90% as determined by HPLC
Endotoxin
Less than 1 EU per μg by the LAL method.
Buffer / Formulation
Lyophilized from 0.22 μm filtered solution in 20mM Tris, 150mM NaCl (pH 7.5). Normally 8% trehalose is added as protectant before lyophilization.
State
Lyophilized
Storage Conditions
-20 to -80°C for 12 months as supplied from date of receipt. -80°C for 3 months after reconstitution. Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Reconstitution Advice
Dissolve the lyophilized protein in distilled water. Please refer to the Certificate of Analysis for detailed instructions.

Data Display

Bis-Tris PAGE
ALK7-HB001 Bis-Tris-PAGE-white result

Biotinylated Human ALK-7 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

SEC-HPLC
ALK7-HB001 SEC-HPLC result

The purity of Biotinylated Human ALK-7 is greater than 90% as determined by SEC-HPLC.

ELISA
ALK7-HB001 ELISA result

Immobilized Biotinylated Human ALK-7, His-Avi tag at 0.5μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-ALK7 Antibody, hFc Tag with the EC50 of 3.8ng/ml determined by ELISA (QC Test).

SPR
ALK7-HB001 SPR result

Anti-ALK-7 Antibody, hFc Tag captured on CM5 Chip via Protein A can bind Biotinylated Human ALK-7, His Tag with an affinity constant of 0.45 nM as determined in SPR assay (Biacore T200).

Background

Arterial stiffness is an important feature of diabetic macrovascular complications. Activin receptor-like kinase 7 (ALK7), a member of type I transforming growth factor-β (TGF-β) receptors, is correlated with pathogenic risks of type 2 diabetes mellitus and cardiovascular diseases and may be involved in cardiovascular remodeling.

References

  1. Li WB, Zhao J, Liu L, Wang ZH, Han L, Zhong M, Zhang Y, Zhang W, Tang MX. Silencing of activin receptor-like kinase 7 alleviates aortic stiffness in type 2 diabetic rats. Acta Diabetol. 2015 Aug;52(4):717-26. doi: 10.1007/s00592-014-0706-8. Epub 2015 Jan 11. PMID: 25577243.

Have questions about this product?

Our technical team can help with product selection, application questions and order support.

Contact Technical Support